INS and Insulin resistance: In this context, evaluating biomarkers related to glucose homeostasis—such as fasting blood glucose, insulin levels, and insulin resistance index (e.g., HOMA-IR, FIRI, QUICKI)—is critical for determining metabolic improvements (Kolb, et al., 2021; Mohamed, et al., 2024).